FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study

BACKGROUND: Fluorouracil, leucovorin (5FU/LV), and nanoliposomal-irinotecan (nal-IRI) combination therapy has been established as the second-line treatment for advanced pancreatic ductal adenocarcinoma. Oxaliplatin with 5FU/LV (FOLFOX) is often used as a subsequent treatment, although its efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Satoshi, Tezuka, Shun, Yamachika, Yui, Tsunoda, Shotaro, Nagashima, Shuhei, Tozuka, Yuichiro, Fukushima, Taito, Morimoto, Manabu, Ueno, Makoto, Furuse, Junji, Maeda, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945590/
https://www.ncbi.nlm.nih.gov/pubmed/36809997
http://dx.doi.org/10.1186/s12885-023-10654-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945590/
https://www.ncbi.nlm.nih.gov/pubmed/36809997
http://dx.doi.org/10.1186/s12885-023-10654-3

Ejemplares similares